Vanguard Global Advisers’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
Vanguard Global Advisers's BMY Position: Q2 2026 in Review
Vanguard Global Advisers reduced its Bristol-Myers Squibb (BMY) stake by 0.72% in Q2 2026, selling an estimated $1.96M and leaving 4,700,737 shares worth $271M. The position accounts for 0.13% of the portfolio, ranked #118.
Vanguard Global Advisers first reported a position in BMY in Q1 2026 and has held it in 2 quarters since. The position peaked at $287M in Q1 2026. 2,401 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Vanguard Global Advisers held 4,700,737 shares of Bristol-Myers Squibb worth $271M as of Q2 2026.
- Vanguard Global Advisers sold 34,179 Bristol-Myers Squibb shares in Q2 2026, an estimated $1.96M.
- Bristol-Myers Squibb made up 0.13% of Vanguard Global Advisers's portfolio in Q2 2026, its #118 holding.
- Vanguard Global Advisers first reported a position in Bristol-Myers Squibb in Q1 2026 and has held it in 2 quarters since.
- Vanguard Global Advisers's Bristol-Myers Squibb position peaked at $287M in Q1 2026.
- 2,401 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.